SUSD3：乳腺癌诊治的潜在靶标  

Sushi domain- containing protein 3: A potential target for the therapy of breast cancer

作　　者：赵爽[1] 陈双双[2] 于正洪[1] 

机构地区：[1]南京大学医学院-南京军区南京总医院肿瘤内科,江苏南京210002 [2]南京中医药大学第一临床医学院肿瘤内科,江苏南京210002

出　　处：《现代肿瘤医学》2016年第9期1493-1496,共4页Journal of Modern Oncology

基　　金：国家自然科学基金资助项目(编号:81272260);江苏省六大人才高峰基金(编号:BK2009284)

摘　　要：芳香化酶抑制剂(AIs)是针对雌激素受体α阳性(ERα+)的绝经后乳腺癌的最有效的内分泌治疗手段。目前用于检测针对药物他莫昔芬敏感性的生物标志物是ERα/孕激素受体(PGR),该标志物只能检测出大约一半的对AI治疗有潜在敏感性的患者。为了检测新型标志物作为AI治疗敏感性的大小,有研究者使用全基因组基因芯片分析,确定了SUSD3(sushi domain-containing protein 3)可以作为AI敏感性的一种新的标志物。乳腺癌组织中缺乏SUSD3的表达是对AI治疗不敏感的乳腺癌最显著的预测指标。如果SUSD3在原发性和转移性乳腺癌均高度表达,而基于抗体的SUSD3靶向治疗可能会成为对抗乳腺癌的新的有效疗法。因此,SUSD3蛋白有可能被用于AI敏感性预测或靶向治疗,来预防、诊断和治疗包括乳腺癌等疾病在内的的雌激素/孕激素依赖性疾病。Aromatase inhibitors （AIs） are the most effective endocrine treatment for estrogen receptor α -positive （ERα ＋ ） postmenopausal breast cancer. The currently used biomarkers for detecting tamoxifen responsiveness, ERα /progesterone receptor （PGR） status can predict only half of the potential responders to AI treatment. Using a genome wide microarray analysis, the researchers identified sushi domain - containing protein 3 （ SUSD3 ） as a novel marker of AI responsiveness. The lack of SUSD3 expression in breast cancer tissue was the most significant predictor for non - responsiveness to AI treatment. We hypothesize that SUSD3 is highly expressed in both primary and metastatic breast cancers and antibody -based targeting SUSD3 can lead to effective new therapeutics to combat breast cancers. Thus, this protein can potentially be measured or targeted for prevention, diagnostic and therapeutic putroses for estrogen/ progesterone -dependent disorders of women including breast cancer.

关 键 词：SUSD3 乳腺癌 芳香化酶抑制剂 

分 类 号：R737.9[医药卫生—肿瘤]